

**REMARKS**

**I. Priority**

In accordance with 35 U.S.C. §119(e) and 35 U.S.C. §120, the Applicants have submitted an amendment containing a specific reference to the prior filed applications in the section above entitled "In the Specification". The Applicants note that a petition and surcharge are not required to correct this priority claim, because the Applicants have amended the first sentence of the specification to contain the specific reference within the later of 4 months from the date on which the National Stage commenced under 35 U.S.C. 371 or 16 months from the filing of the prior filed application.

**II. Information Disclosure Statement**

The Applicants submit that a copy of the Information Disclosure Statement has been enclosed herewith. As such, the Applicants respectfully request consideration of the enclosed Information Disclosure Statement and further request that all references cited herein be printed on the face of the patent upon grant of the present application.


**Conclusion**

The Applicants respectfully request entry of the present amendment.

If the Examiner believes that a telephone conference would expedite the prosecution of this application, please telephone the undersigned at 734-622-7304.

Dated: 8/8/06

Respectfully submitted,



David R. Kurlandsky  
Registration No. 41,505  
Pfizer, Inc.  
2800 Plymouth Road  
Ann Arbor, MI 48105  
Telephone: (734) 622-7304  
Facsimile: (734) 622-1553